LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Search results

Result 1 - 3 of total 3

Search options

  1. Article: Vademecum for the treatment of people with COVID-19. Edition 2.0, 13 March 2020.

    Lombardy Section Italian Society Infectious And Tropical Diseases, -

    Le infezioni in medicina

    2020  Volume 28, Issue 2, Page(s) 143–152

    Abstract: ... of the Italian Society of Infectious and Tropical Diseases provided this «vademecum» with the aim to explore ... The spread of COVID-19 epidemic in Italy, and particularly in Lombardy determined the need ... However, no specific drug has been previously approved for the COVID-19 treatment. The Lombardy Section ...

    Abstract The spread of COVID-19 epidemic in Italy, and particularly in Lombardy determined the need to standardize the therapeutic approach in order to offer the same indications for all hospitals in Lombardy. However, no specific drug has been previously approved for the COVID-19 treatment. The Lombardy Section of the Italian Society of Infectious and Tropical Diseases provided this «vademecum» with the aim to explore the current evidence about the drugs likely to be efficacious in the treatment of COVID-19. Moreover, a multidisciplinary group including critical care specialists has been created in order to provide indications about supporting measures and the use of steroids. A new grading scale has been proposed to help patients' stratification according to the severity of the respiratory conditions. Lastly, a collaborating group with immunologists and rheumatologists has been built with the aim of providing some guidance about the use of tocilizumab, a promising option for the treatment of the hyperinflammatory state occurring in most patients affected by COVID-19.
    MeSH term(s) Adenosine Monophosphate/analogs & derivatives ; Adenosine Monophosphate/therapeutic use ; Alanine/analogs & derivatives ; Alanine/therapeutic use ; Antibodies, Monoclonal, Humanized/therapeutic use ; Antiviral Agents/therapeutic use ; Betacoronavirus/isolation & purification ; COVID-19 ; Clinical Protocols/standards ; Coronavirus Infections/drug therapy ; Coronavirus Infections/epidemiology ; Coronavirus Infections/therapy ; Humans ; Italy/epidemiology ; Pandemics ; Patient Care Team ; Patient Selection ; Pneumonia, Viral/drug therapy ; Pneumonia, Viral/epidemiology ; Pneumonia, Viral/therapy ; SARS-CoV-2
    Chemical Substances Antibodies, Monoclonal, Humanized ; Antiviral Agents ; remdesivir (3QKI37EEHE) ; Adenosine Monophosphate (415SHH325A) ; tocilizumab (I031V2H011) ; Alanine (OF5P57N2ZX)
    Keywords covid19
    Language English
    Publishing date 2020-04-10
    Publishing country Italy
    Document type Journal Article ; Practice Guideline ; Review
    ZDB-ID 2041081-5
    ISSN 1124-9390
    ISSN 1124-9390
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  2. Article: Vademecum for the treatment of people with COVID-19. Edition 2.0, 13 March 2020

    Lombardy Section Italian Society Infectious And Tropical Diseases, -

    Infez Med

    Abstract: ... of the Italian Society of Infectious and Tropical Diseases provided this «vademecum¼ with the aim to explore ... The spread of COVID-19 epidemic in Italy, and particularly in Lombardy determined the need ... However, no specific drug has been previously approved for the COVID-19 treatment. The Lombardy Section ...

    Abstract The spread of COVID-19 epidemic in Italy, and particularly in Lombardy determined the need to standardize the therapeutic approach in order to offer the same indications for all hospitals in Lombardy. However, no specific drug has been previously approved for the COVID-19 treatment. The Lombardy Section of the Italian Society of Infectious and Tropical Diseases provided this «vademecum¼ with the aim to explore the current evidence about the drugs likely to be efficacious in the treatment of COVID-19. Moreover, a multidisciplinary group including critical care specialists has been created in order to provide indications about supporting measures and the use of steroids. A new grading scale has been proposed to help patients' stratification according to the severity of the respiratory conditions. Lastly, a collaborating group with immunologists and rheumatologists has been built with the aim of providing some guidance about the use of tocilizumab, a promising option for the treatment of the hyperinflammatory state occurring in most patients affected by COVID-19.
    Keywords covid19
    Publisher WHO
    Document type Article
    Note WHO #Covidence: #32275256
    Database COVID19

    Kategorien

  3. Article: Vademecum for the treatment of people with COVID-19. Edition 2.0, 13 March 2020

    Lombardy Section Italian Society Infectious And Tr, -

    Infez Med

    Abstract: ... of the Italian Society of Infectious and Tropical Diseases provided this «vademecum¼ with the aim to explore ... The spread of COVID-19 epidemic in Italy, and particularly in Lombardy determined the need ... However, no specific drug has been previously approved for the COVID-19 treatment. The Lombardy Section ...

    Abstract The spread of COVID-19 epidemic in Italy, and particularly in Lombardy determined the need to standardize the therapeutic approach in order to offer the same indications for all hospitals in Lombardy. However, no specific drug has been previously approved for the COVID-19 treatment. The Lombardy Section of the Italian Society of Infectious and Tropical Diseases provided this «vademecum¼ with the aim to explore the current evidence about the drugs likely to be efficacious in the treatment of COVID-19. Moreover, a multidisciplinary group including critical care specialists has been created in order to provide indications about supporting measures and the use of steroids. A new grading scale has been proposed to help patients' stratification according to the severity of the respiratory conditions. Lastly, a collaborating group with immunologists and rheumatologists has been built with the aim of providing some guidance about the use of tocilizumab, a promising option for the treatment of the hyperinflammatory state occurring in most patients affected by COVID-19.
    Keywords covid19
    Publisher WHO
    Document type Article
    Note WHO #Covidence: #32275256
    Database COVID19

    Kategorien

To top